BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 14983408)

  • 1. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.
    Herrmann BL; Berg C; Vogel E; Nowak T; Renzing-Koehler K; Mann K; Saller B
    Horm Metab Res; 2004 Jan; 36(1):54-61. PubMed ID: 14983408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.
    Herrmann BL; Saller B; Stratmann M; Berg C; Mann K; Janssen OE
    Horm Metab Res; 2005 Jan; 37(1):49-52. PubMed ID: 15702440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
    Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.
    Johannsson G; Mårin P; Lönn L; Ottosson M; Stenlöf K; Björntorp P; Sjöström L; Bengtsson BA
    J Clin Endocrinol Metab; 1997 Mar; 82(3):727-34. PubMed ID: 9062473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of recombinant human growth hormone on glucose metabolism in children with growth hormone deficiency].
    Liang L; Zou CC; Li Y; Wang CL; Jiang YJ; Dong GP; Fu JF; Wang XM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):657-61. PubMed ID: 17217656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
    Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial.
    Franco C; Brandberg J; Lönn L; Andersson B; Bengtsson BA; Johannsson G
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1466-74. PubMed ID: 15598680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults.
    Rosenfalck AM; Maghsoudi S; Fisker S; Jørgensen JO; Christiansen JS; Hilsted J; Vølund AA; Madsbad S
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4173-81. PubMed ID: 11095450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity.
    Albert SG; Mooradian AD
    J Clin Endocrinol Metab; 2004 Feb; 89(2):695-701. PubMed ID: 14764783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy.
    Christopher M; Hew FL; Oakley M; Rantzau C; Alford F
    J Clin Endocrinol Metab; 1998 May; 83(5):1668-81. PubMed ID: 9589675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.
    Glesby MJ; Albu J; Chiu YL; Ham K; Engelson E; He Q; Muthukrishnan V; Ginsberg HN; Donovan D; Ernst J; Lesser M; Kotler DP
    PLoS One; 2013; 8(4):e61160. PubMed ID: 23593417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.
    Florakis D; Hung V; Kaltsas G; Coyte D; Jenkins PJ; Chew SL; Grossman AB; Besser GM; Monson JP
    Clin Endocrinol (Oxf); 2000 Oct; 53(4):453-9. PubMed ID: 11012570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.
    Vittone J; Blackman MR; Busby-Whitehead J; Tsiao C; Stewart KJ; Tobin J; Stevens T; Bellantoni MF; Rogers MA; Baumann G; Roth J; Harman SM; Spencer RG
    Metabolism; 1997 Jan; 46(1):89-96. PubMed ID: 9005976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women.
    Tagliaferri M; Scacchi M; Pincelli AI; Berselli ME; Silvestri P; Montesano A; Ortolani S; Dubini A; Cavagnini F
    Int J Obes Relat Metab Disord; 1998 Sep; 22(9):836-41. PubMed ID: 9756240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of short-term administration of low-dose rhGH on IGF-I levels in obesity and Cushing's syndrome: indirect evaluation of sensitivity to GH.
    Maccario M; Tassone F; Gauna C; Oleandri SE; Aimaretti G; Procopio M; Grottoli S; Pflaum CD; Strasburger CJ; Ghigo E
    Eur J Endocrinol; 2001 Mar; 144(3):251-6. PubMed ID: 11248744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.